Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Public ClinicalTrials.gov record NCT04068597. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Study identification
- NCT ID
- NCT04068597
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Interventions
- CCS1477 Drug
- Pomalidomide Drug
- Dexamethasone Drug
- Azacitidine Drug
- Venetoclax Drug
- Bortezomib Drug
- Ixazomib Drug
- Elranatamab Drug
- Teclistamab Drug
- Lenalidomide Drug
- Daratumumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 8, 2019
- Primary completion
- Mar 30, 2027
- Completion
- Mar 30, 2027
- Last update posted
- Jun 23, 2026
2019 – 2027
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Emory Winship Cancer Institute | Atlanta | Georgia | 30322 | Recruiting |
| Community Health Network | Indianapolis | Indiana | 46227 | Recruiting |
| The Center for Cancer and Blood Disorders (CCBD) | Bethesda | Maryland | 20817 | Recruiting |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | Recruiting |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198-6846 | Recruiting |
| Penn Medicine - Abramson Cancer Center Perelman | Philadelphia | Pennsylvania | 19104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04068597, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 23, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04068597 live on ClinicalTrials.gov.